Engineered CRISPRs (Clustered Regularly Interspaced Short Palindromic Repeats) have gone from proof-of-concept to an FDA-approved drug in little more than a decade (Fig. 1). This shrunken bench-to-beside timeline was a result of data from clinical trials where single doses lead to effective long-term cures (or predictions for cure) in essentially all treated patients. [1–3] Such remarkable results have been seen for both ex vivo applications in hematologic disorders—where bone marrow–derived cells were gene-edited and reintroduced into the patient [1]—as well as for somatic in vivo gene-editing in systemic protein-folding disorders, where therapeutic components were delivered by intravenous injections [2]. Several other gene-editing clinical trials for chronic bacterial infections, inflammatory diseases, cancers, cardiovascular diseases, HIV/AIDS, diabetes, and autoimmune diseases are ongoing [4], and this new way of treating human disease seems poised to change medical practice. Given this backdrop, it seems imperative to test this new class of medicines in neurodegenerative illnesses such as Alzheimer’s disease (AD), where traditional therapeutics have been largely disappointing.